Envestnet Portfolio Solutions
NKTR icon

Envestnet Portfolio Solutions’s Nektar Therapeutics NKTR Stock Holding History

Envestnet Portfolio Solutions’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-779
Closed -$10.9K – 1678
2024
Q1 		$10.9K Sell
779
-1,084
-58% -$11.3K ﹤0.01% 1596
2023
Q4 		$15.8K Sell
1,863
-779
-29% -$5.9K ﹤0.01% 1531
2023
Q3 		$23.6K Buy
+2,642
New +$25.4K ﹤0.01% 1478

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Envestnet Portfolio Solutions's NKTR Position: Q2 2024 in Review

Envestnet Portfolio Solutions sold out of Nektar Therapeutics (NKTR) in Q2 2024, closing a stake of 779 shares — an estimated $10.9K sold.

Envestnet Portfolio Solutions first reported a position in NKTR in Q3 2023 and held it in 3 quarters. The position peaked at $23.6K in Q3 2023. 133 funds tracked by Wall St. Rank hold NKTR as of Q2 2024.

  • Envestnet Portfolio Solutions reported no remaining Nektar Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Envestnet Portfolio Solutions sold 779 Nektar Therapeutics shares in Q2 2024, an estimated $10.9K.
  • Envestnet Portfolio Solutions first reported a position in Nektar Therapeutics in Q3 2023 and held it in 3 quarters.
  • Envestnet Portfolio Solutions's Nektar Therapeutics position peaked at $23.6K in Q3 2023.
  • 133 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2024.

Based on Envestnet Portfolio Solutions's 13F filing for Q2 2024, filed 16 Jul 2024.